Novo Nordisk's Pipeline Humming, but Shares Remain Stuck in Neutral

Novo Nordisk closed the week at €37.35, slipping 4.35% over seven days as a barrage of pipeline announcements failed to lift the stock out of its rut. The Danish drugmaker has lost 16.4% since the start of the year and a startling 41.4% over the past twelve months. With a relative strength index of 48.8, the shares sit in no-man's land — neither oversold nor showing momentum.

Yet behind the price action, the pipeline is buzzing. Positive Phase-2 data for the experimental diabetes therapy Zenagamtide, a novel clinical partnership with Veru Inc. to preserve muscle mass during weight loss, and the international rollout of an oral version of Wegovy all underscore a company pushing ahead on multiple fronts. The market, however, is looking past near-term science toward the headwind of US pricing pressure and the looming loss of semaglutide exclusivity in several countries.

Zenagamtide Hits the Mark, Phase-3 on Deck

Data presented at the American Diabetes Association conference showed that 262 patients with type 2 diabetes given Zenagamtide achieved a HbA1c reduction of 1.71 percentage points in the 40?milligram arm — from 7.8% to below 7.0%. Only 0.14 points were shaved off in the placebo group. Crucially, 89.1% of those on the highest dose hit the glycaemic target. Meanwhile, average weight loss reached 14.6% after 36 weeks. Novo Nordisk intends to launch Phase?3 studies in the second half of 2026, placing Zenagamtide as a potential successor in the GLP?1 lineage.

A New Combo Play: Wegovy Meets Muscle Preservation

In a separate move, Novo Nordisk signed a clinical supply agreement with Veru Inc. under which Novo provides Wegovy (semaglutide) for Veru's Phase?2b PLATEAU study. The trial will test Veru's oral selective androgen receptor modulator, enobosarm, in combination with Wegovy in older adults with obesity. The goal is to shed fat without losing lean muscle mass — a frequent concern with aggressive weight loss. In exchange, Novo Nordisk secures first negotiation rights for any future combination therapy involving GLP?1 agonists.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

The market reaction was lopsided: Veru's stock shot up more than 167% on the day of the disclosure, while Novo Nordisk managed only a 4% gain on Thursday — far from enough to offset the week's losses.

Oral Wegovy Gains Traction, Abroad and at Home

After winning US approval in December 2025, the pill version of Wegovy has been rolled out in the United Arab Emirates, and the European Medicines Agency has recommended EU approval — a green light from the European Commission is widely expected. US demand has been fierce: 1.3 million prescriptions were written in the first quarter of 2026, pushing the total since the early?January launch past two million.

Early?Stage Candidates Enter the Lab

Two novel Phase?1 programmes are also quietly recruiting. NNC0497?0040, launched in May 2026, is a randomised, quadruple?blind safety study — patients, physicians, study staff and outcome assessors are all kept in the dark about who gets the active drug. A second candidate, NNC0113?5840, an injectable obesity agent, was filed in April and is also enrolling. Both are still at the earliest safety?testing stage, with clinically meaningful data years away.

All Eyes on the ADA Investor Day and CagriSema

Novo Nordisk will host an R&D investor day on Sunday, 7 June, on the margins of the ADA annual meeting in New Orleans. The company plans to showcase 40 abstracts, including Phase?3 data for CagriSema — a fixed?dose combination of semaglutide and the experimental amylin analogue cagrilintide. CagriSema was submitted to US regulators in December 2025, with a decision expected in the fourth quarter of 2026. Fresh mid?stage Zenagamtide data will also be presented.

Buyback Cushions, but Analysts Remain Divided

A share?repurchase programme of up to 11.2 billion Danish kroner, running through February 2027, is providing a mechanical floor. By the end of May, Novo Nordisk had bought back roughly 17.9 million B?shares at an average price of around 263 kroner each.

Novo Nordisk at a turning point? This analysis reveals what investors need to know now.

Analyst opinion is split. Of 23 brokerages tracked, 18 rate the stock a "hold", four say "buy", and one recommends "sell". The average price target stands at $65.56. Goldman Sachs reaffirmed its hold rating on 3 June. The divergence reflects contrasting assumptions about US pricing pressure on Wegovy, the pace of international pill rollouts in the second half, and competitive threats from Eli Lilly's tirzepatide.

Technically, the stock trades about 10% below its 200?day moving average of €41.67. It has recouped some ground since hitting a low of €30.25 in March, but remains nearly 47% off the June 2025 peak of €70. Novo Nordisk itself has guided for a 5%?13% decline in both revenue and operating profit for 2026, citing expiring semaglutide exclusivity in several markets and US pricing headwinds. The next set of quarterly numbers is due on 5 August.

Pipeline progress aside, the shares are caught between promising science and a grim near?term outlook. Whether Zenagamtide and CagriSema can ultimately shift the narrative will depend on the data — and on how quickly the oral Wegovy pill can conquer market share abroad.

Ad

Novo Nordisk Stock: New Analysis - 6 June

Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Novo Nordisk analysis...

en | DK0062498333 | NOVO | boerse | 69492542 |